Navigation Links
Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
Date:10/20/2008

NEW HAVEN, Conn., Oct. 20 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that it will present a poster entitled "A Phase 2 Study Comparing Two Doses of Radezolid to Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI)" at the 2008 ICAAC/IDSA Joint Meeting in Washington, D.C. Details on the presentation are as follows:

Poster Session: New Treatment Options in Skin and Soft

Tissue Infections

Poster Title: A Phase 2 Study Comparing Two Doses of

Radezolid to Linezolid in Adults with

Uncomplicated Skin and Skin Structure

Infections (uSSSI)

Date: Sunday, October 26, 2008

Time: 12:15pm ET - 1:15pm ET

Location: Hall C

"We are extremely proud to have been selected to present at the leading global antimicrobials conference," said Susan Froshauer, PhD, President and Chief Executive Officer, Rib-X Pharmaceuticals. "These data result from one of two proof-of-concept phase 2 trials with radezolid, a compound which derives from the Rib-X proprietary drug discovery approach. It is an honor to have our work recognized by the ICAAC/IDSA joint meeting organizers."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. Radezolid (RX-1741), an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococci pneumonia and S. pyogenes. Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active against a broad spectrum of bacteria, including quinolone resistant Gram positive bacteria and MRSA. Both radezolid and delafloxacin are currently in Phase 2 clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at http://www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
2. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
3. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
4. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
5. Amylin Pharmaceuticals to Webcast Third Quarter Results
6. Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services
7. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
9. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
10. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
11. Ukrainian President Yushchenko: Pharmaceuticals Very Important
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of ... trends in analytical testing are being attributed to new regulatory requirements for all ...
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):